Comment on: "Fenofibrate therapy in reducing the progression of diabetic retinopathy: revisiting the FIELD and ACCORD-EYE studies through the LENS trial ".
作者信息
Liu Yu-Chi, Mehta Jodhbir S, Tan Hong Chang
机构信息
Department of Cornea and External Eye Disease, Singapore National Eye Centre, Singapore, Singapore.
Ophthalmology and Visual Sciences Academic Clinical Program, Duke-NUS Medical School, Singapore, Singapore.
出版信息
Eye (Lond). 2025 Jul;39(10):2106. doi: 10.1038/s41433-025-03866-3. Epub 2025 May 19.
Abstract
摘要
相似文献
1
Comment on: "Fenofibrate therapy in reducing the progression of diabetic retinopathy: revisiting the FIELD and ACCORD-EYE studies through the LENS trial ".
Eye (Lond). 2025 Jul;39(10):2106. doi: 10.1038/s41433-025-03866-3. Epub 2025 May 19.
2
Cost-effectiveness of fenofibrate versus standard care for reducing the progression of diabetic retinopathy: An economic evaluation based on data from the LENS trial.
Diabet Med. 2025 Jul 3:e70098. doi: 10.1111/dme.70098.
3
Fenofibrate for diabetic retinopathy.
Cochrane Database Syst Rev. 2023 Jun 13;6(6):CD013318. doi: 10.1002/14651858.CD013318.pub2.
4
Randomised, multicentre, placebo-controlled trial of fenofibrate for treatment of diabetic macular oedema with economic evaluation (FORTE study): study protocol for a randomised control trial.
BMJ Open. 2024 Dec 20;14(12):e089518. doi: 10.1136/bmjopen-2024-089518.
5
Fenofibrate therapy in reducing the progression of diabetic retinopathy: revisiting the FIELD and ACCORD-EYE studies through the LENS trial.
Eye (Lond). 2025 Jan;39(1):15-17. doi: 10.1038/s41433-024-03410-9. Epub 2024 Oct 22.
6
Effect of micronized fenofibrate on microvascular complications of type 2 diabetes: a systematic review.
Expert Opin Pharmacother. 2016 Aug;17(11):1463-73. doi: 10.1080/14656566.2016.1195811. Epub 2016 Jun 15.
7
Blood pressure control for diabetic retinopathy.
Cochrane Database Syst Rev. 2023 Mar 28;3(3):CD006127. doi: 10.1002/14651858.CD006127.pub3.
8
Fenofibrate Exerts Protective Effects in Diabetic Retinopathy.
Curr Eye Res. 2025 Jun 18:1-9. doi: 10.1080/02713683.2025.2516802.
9
Anti-VEGF drugs compared with laser photocoagulation for the treatment of proliferative diabetic retinopathy: a systematic review and individual participant data meta-analysis.
Health Technol Assess. 2025 Apr 2:1-75. doi: 10.3310/MJYP6578.
10
Anti-VEGF drugs compared with laser photocoagulation for the treatment of diabetic retinopathy: a systematic review and meta-analysis.
Health Technol Assess. 2024 Dec 11:1-71. doi: 10.3310/PCGV5709.
本文引用的文献
1
Fenofibrate therapy in reducing the progression of diabetic retinopathy: revisiting the FIELD and ACCORD-EYE studies through the LENS trial.
Eye (Lond). 2025 Jan;39(1):15-17. doi: 10.1038/s41433-024-03410-9. Epub 2024 Oct 22.
2
Interconnections between diabetic corneal neuropathy and diabetic retinopathy: diagnostic and therapeutic implications.
Neural Regen Res. 2025 Aug 1;20(8):2169-2180. doi: 10.4103/NRR.NRR-D-24-00509. Epub 2024 Sep 20.
3
Topical and oral peroxisome proliferator-activated receptor-α agonist ameliorates diabetic corneal neuropathy.
Sci Rep. 2024 Jun 11;14(1):13435. doi: 10.1038/s41598-024-64451-4.
4
Oral Peroxisome Proliferator-Activated Receptor-α Agonist Enhances Corneal Nerve Regeneration in Patients With Type 2 Diabetes.
Diabetes. 2023 Jul 1;72(7):932-946. doi: 10.2337/db22-0611.
5
Neurodegeneration of the cornea and retina in patients with type 1 diabetes without clinical evidence of diabetic retinopathy.
Front Endocrinol (Lausanne). 2022 Oct 5;13:790255. doi: 10.3389/fendo.2022.790255. eCollection 2022.
6
Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial.
Lancet. 2009 May 23;373(9677):1780-8. doi: 10.1016/S0140-6736(09)60698-X.
Zotero 插件